Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Sharon Bio-Medicine Ltd (SHARONBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532908 NSE: SHARONBIO Pharmaceuticals & Drugs | Small Cap | Sharon Bio-Medicine Share Price
BSE Share Price
Not Listed
Not Listed
Sharon Bio-Medicine Ltd (SHARONBIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532908 NSE: SHARONBIO Pharmaceuticals & Drugs | Small Cap | Sharon Bio-Medicine Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹2 Cr.
Current Price
₹0
52-Week Low / High
₹3 / 5
TTM EPS
₹-406.4
TTM Sales
₹838 Cr.
Book Value per Share
₹-394.2
P/E Ratio
0.00
Industry PE
55.3
Price to Book (P/B)
-0.01
Price to Sales (P/S)
0.00
EV/EBITDA
-26.04
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Return on Capital Employed (ROCE)
-27.83%
Return on Assets (ROA)
-34.62%
Operating Profit Margin
-52.8%
Net Profit Margin
-118.47%
Gross Profit Margin
-80.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
21.76%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-228 Cr.
Equity
₹1.2 Cr.
Face Value
₹2
All Time Low / High
₹2.60 / 90.20
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Jun'13 | Jun'14 | Jun'15 | Mar'16 | Mar'17 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 13.8% | 14.7% | -12.8% | -27.7% | -77.2% | 4.3% | 9.8% | 43.2% | 25.2% | 36.1% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1,060 | 1,314 | 834 | 338 | 139 | 188 | 192 | 190 | 197 | 240 | 190 |
| Sales YoY Gr. | - | 24% | -36.5% | -59.5% | -58.9% | 35.7% | 2% | -1% | 3.8% | 21.8% | - |
| Adj EPS ⓘ | 5 | 6.6 | -14.5 | -27.9 | -28.4 | 29.2 | 30.8 | 36,496.6 | 8,238.5 | 13,926.9 | 33 |
| YoY Gr. | - | 31.5% | -319.7% | NA | NA | NA | 5.6% | 118433.9% | -77.4% | 69.1% | - |
| BVPS (₹) ⓘ | 17.9 | 24.1 | 8 | -22.9 | -46.7 | -1,130 | -1,068.1 | 10,056.4 | 19,532.4 | 36,153.2 | -1,161.5 |
| Adj Net Profit ⓘ | 52.9 | 69.6 | -172 | -332 | -338 | 16.8 | 17.7 | 87.5 | 19.8 | 33.4 | 19 |
| Cash Flow from Ops. ⓘ | -70.2 | -69.5 | -81.9 | -37.6 | 33.9 | 23 | 41.1 | 66.9 | 38.2 | 45.1 | - |
| Debt/CF from Ops. ⓘ | -9.2 | -10.4 | -10.1 | -29.7 | 21.4 | 36 | 20.1 | 2.1 | 3.2 | 1.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -15.2% | 11.6% | 7.8% | 21.8% | ||||
| Adj EPS ⓘ | 141.4% | NA | 667.6% | 69.1% | ||||
| BVPSⓘ | 133% | NA | NA | 85.1% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Jun'13 | Jun'14 | Jun'15 | Mar'16 | Mar'17 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 24.2 | 23.7 | -74.6 | 786.2 | 91.8 | -2.9 | -2.9 | -29.7 | 53.4 | 48 | 0.2 |
| Op. Profit Mgn % ⓘ | 11.4 | 12 | -4.1 | -52.8 | -220.2 | 13.9 | 12.5 | 14.4 | 22.1 | 24.6 | 13.3 |
| Net Profit Mgn % ⓘ | 5 | 5.3 | -20.7 | -98.3 | -243.7 | 8.9 | 9.2 | 46 | 10 | 13.9 | 10 |
| Debt to Equity ⓘ | 3.4 | 2.9 | 8.7 | -4.1 | -1.3 | -1.3 | -1.4 | 5.6 | 2.5 | 1 | - |
| Working Cap Days ⓘ | 198 | 202 | 322 | 761 | 586 | 164 | 190 | 154 | 150 | 148 | 161 |
| Cash Conv. Cycle ⓘ | 165 | 169 | 272 | 657 | 467 | 9 | 31 | 43 | 78 | 86 | -160 |
Valuation of Sharon Bio-Medicine - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 334.62 | 419.79 | 522.98 | 626.81 | 804.14 | 1,073.52 | 1,324.79 | 838.46 | 253.45 |
| Operating Expenses ⓘ + | 295.54 | 380.96 | 469.80 | 554.43 | 708.01 | 952.48 | 1,167.28 | 872.89 | 387.30 |
| Operating Profit ⓘ | 39.08 | 38.83 | 53.17 | 72.39 | 96.13 | 121.03 | 157.51 | -34.43 | -133.85 |
| Operating Profit Margin (%) | 11.7% | 9.3% | 10.2% | 11.5% | 12.0% | 11.3% | 11.9% | -4.1% | -52.8% |
| Other Income ⓘ + | 2.51 | 1.93 | 1.86 | 1.41 | 1.24 | 1.19 | 1.93 | 2.63 | 1.95 |
| Interest ⓘ | 6.59 | 14.36 | 21 | 26.81 | 34.26 | 43.06 | 58.63 | 93.65 | 70.98 |
| Depreciation ⓘ | 3.60 | 4.18 | 6.40 | 8.34 | 8.86 | 12.13 | 15.35 | 19.17 | 15.01 |
| Profit Before Tax ⓘ | 31.39 | 22.22 | 27.63 | 38.49 | 54.21 | 67.04 | 85.46 | -229.24 | -290.30 |
| Tax ⓘ | 4.21 | 3.59 | 5.31 | 5.31 | 11.44 | 13.33 | 15.14 | 4.66 | 9.97 |
| Profit After Tax | 27.19 | 18.63 | 22.33 | 33.18 | 42.77 | 53.71 | 70.32 | -233.90 | -300.27 |
| PAT Margin (%) | 8.1% | 4.4% | 4.3% | 5.3% | 5.3% | 5.0% | 5.3% | -27.9% | -118.0% |
| Adjusted EPS (₹) | 2.6 | 1.8 | 2.1 | 3.1 | 4.1 | 5.1 | 6.7 | -19.7 | -25.3 |
| Dividend Payout Ratio (%) | 4.70% | 6.80% | 7.10% | 5.70% | 4.40% | 3% | 5.40% | 0% | 0% |
| PARTICULARS | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Mar'16 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 80.98 | 98.14 | 118.59 | 149.53 | 145.14 | 196.92 | 271.75 | 104.73 | -195.22 | ||
| Debt + | 214.45 | 262.41 | 342.56 | 343.62 | 507.54 | 643.89 | 725.38 | 821.08 | 836.32 | ||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Trade Payables | 25.42 | 22.66 | 33.40 | 35.14 | 50.15 | 60.06 | 61.37 | 54.71 | 40.04 | ||
| Others Liabilities ⓘ | 9.07 | 14.14 | 17.02 | 67.36 | 78.65 | 79.01 | 110.96 | 31.48 | 41.70 | ||
| Total Liabilities ⓘ | 329.92 | 397.34 | 511.57 | 595.65 | 781.47 | 979.88 | 1,169.47 | 1,012.01 | 722.84 | ||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 56.68 | 56.12 | 183.77 | 180.85 | 201.33 | 271.55 | 325.02 | 332.10 | 318.56 | ||
| CWIP ⓘ | 43.86 | 106.91 | 22.74 | 27.04 | 59.90 | 42.82 | 14.93 | 0 | 0 | ||
| Investments ⓘ | 0.64 | 0.64 | 3.49 | 3.24 | 3.34 | 3.34 | 0.59 | 0.39 | 0.06 | ||
| Inventories | 57.75 | 89.66 | 116.67 | 155.21 | 196.22 | 260.24 | 322.45 | 301.42 | 179.99 | ||
| Trade Receivables | 94.94 | 133.46 | 170.18 | 202.92 | 268.22 | 363.52 | 422.61 | 316.22 | 183.18 | ||
| Cash Equivalents | 72.66 | 3.38 | 2.40 | 3.87 | 6.31 | 6.32 | 12.34 | 15.92 | 10.16 | ||
| Others Assets ⓘ | 3.38 | 7.17 | 12.33 | 22.53 | 46.15 | 32.11 | 71.53 | 45.94 | 30.90 | ||
| Total Assets ⓘ | 329.92 | 397.34 | 511.57 | 595.65 | 781.47 | 979.88 | 1,169.47 | 1,012.01 | 722.84 | ||
| PARTICULARS | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -40.46 | -50.78 | -28.11 | -36.25 | -53.43 | -70.44 | -69.62 | -83.50 | -31.49 |
| Cash Flow From Investing Activity ⓘ + | -41.46 | -65.30 | -51.16 | -7.95 | -60.97 | -63.98 | -27.12 | -10.06 | -0.50 |
| Cash Flow From Financing Activity ⓘ + | 154.15 | 46.84 | 78.28 | 45.67 | 116.85 | 134.43 | 102.77 | 97.14 | 26.22 |
| Net Cash Flow ⓘ | 72.23 | -69.23 | -0.99 | 1.47 | 2.45 | 0.01 | 6.02 | 3.58 | -5.77 |
| PARTICULARS | Jun'08 | Jun'09 | Jun'10 | Jun'11 | Jun'12 | Jun'13 | Jun'14 | Jun'15 | Mar'16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 33.8 | 20.91 | 20.68 | 24.82 | 29.1 | 31.47 | 30.65 | -130.79 | N/A | |
| ROCE (%) | 12.54 | 10.9 | 11.62 | 12.85 | 14.1 | 13.74 | 14.68 | -13.57 | N/A | |
| Asset Turnover Ratio | 1.01 | 1.15 | 1.15 | 1.13 | 1.17 | 1.22 | 1.23 | 0.77 | 0.29 | |
| PAT to CFO Conversion(x) | -1.49 | -2.73 | -1.26 | -1.09 | -1.25 | -1.31 | -0.99 | N/A | N/A | |
| Working Capital Days | ||||||||||
| Receivable Days | 103.60 | 99.30 | 106 | 108.60 | 106.90 | 107.40 | 108.30 | 160.80 | 359.60 | |
| Inventory Days | 63 | 64.10 | 72 | 79.20 | 79.80 | 77.60 | 80.30 | 135.80 | 346.60 | |
| Payable Days | 32.60 | 24.10 | 23.20 | 23.90 | 23.10 | 22 | 19.70 | 26.10 | 52 | |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Sharon Bio-Medicine Ltd FAQs
The current trading price of Sharon Bio-Medicine on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sharon Bio-Medicine stood at ₹1.85 Cr
The latest P/E ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.10.
The latest P/B ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.00.
The 52-week high of Sharon Bio-Medicine is ₹4.65 and the 52-week low is ₹3.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharon Bio-Medicine is ₹190 ( Cr.) .
Data is not available for this company.
The key valuation ratios of Sharon Bio-Medicine Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
No data found
About Sharon Bio-Medicine Ltd
Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).
The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.
With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.
The company’s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.
It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.
Products
- APIs and Pellets
- Intermediates
- Formulations
Milestones
- 1995 - The current management took over and started manufacturing of pharma intermediates
- 1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
- 2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
- 2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
- 2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
- 2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
- 2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
